| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | VX-680 | GDSC1000 | pan-cancer | AAC | -0.17 | 0.002 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | purmorphamine | CTRPv2 | pan-cancer | AAC | 0.12 | 0.002 |
| mRNA | lenvatinib | CTRPv2 | pan-cancer | AAC | 0.12 | 0.002 |
| mRNA | GDC-0941 | GDSC1000 | pan-cancer | AAC | -0.1 | 0.002 |
| mRNA | BX-795 | GDSC1000 | pan-cancer | AAC | -0.11 | 0.002 |
| mRNA | BRD1812 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | vincristine | CTRPv2 | pan-cancer | AAC | 0.096 | 0.002 |
| mRNA | BRD-K35604418 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.003 |
| mRNA | CEP-701 | GDSC1000 | pan-cancer | AAC | -0.099 | 0.003 |